Investor Presentation Q1 2022
18
Investor presentation
First three months of 2022
Financial outlook for 2022
Sales growth - at CER
Expectations
29 April 2022
10% to 14%
Expectations
2 Feb 2022
6% to 10%
Sales growth - reported
Operating profit growth - at CER
Operating profit growth - reported
Around 7 percentage points higher
9% to 13%
Around 11 percentage points higher
Around 5 percentage points higher
4% to 8%
Around 7 percentage points higher
Financial items (net)
Effective tax rate
Free cash flow
Loss of around DKK 4.1 billion
20% to 22%
DKK 55 to 60 billion
Loss of around DKK 2.8 billion
20% to 22%
DKK 50 to 55 billion
Note: Changes since last highlighted in bold
The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 28 April 2022
Novo NordiskⓇView entire presentation